COMMUNIQUÉS West-GlobeNewswire

Vera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine
22/10/2026
TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, achieved statistical significance in all prespecified endpoints, including eGFR change from baseline and annualized slope, and risk reduction in [...]
Alignment Health Adds New Medicare Advantage Plan in Pima County, Increasing Access and Choice for Arizona Seniors
22/10/2026
New plan strengthens Alignment’s Arizona portfolio available to nearly 1.1 million Medicare beneficiaries across Maricopa, Pima and Santa Cruz counties PHOENIX, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Alignment Health Plan, [...]
Guerbet : Revenue at 30 September 2026.
22/10/2026
Revenue at 30 September 2026 Business in line with Group expectations Revenue at 30 September 2026 of €573.8m, down 1.3% at CER 1 and like-for-like 2 ; excluding China, business grew by 1%, with a positive contribution [...]
Guerbet : Chiffre d’affaires au 30 septembre 2026.
22/10/2026
Chiffre d’affaires au 30 septembre 2026 Une activité conforme aux anticipations du Groupe Chiffre d’affaires au 30 septembre 2026 de 573,8 M€, en repli de 1,3% à TCC 1 et périmètre comparable 2 ; hors Chine, une [...]
One04 Therapeutics presents positive interim Phase 1 data for CPV-104 in C3 glomerulopathy in ASN Kidney Week late-breaker
22/10/2026
Met predefined primary and secondary objectives for the interim analysis CPV-104 was generally well tolerated in healthy volunteers and patients with C3 glomerulopathy (C3G) Exploratory analyses in patients with C3G [...]
Regulated information: Disclosure of a transparency notification from Aberdeen Group plc
22/10/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 22 October 2026 – 6 PM CET Disclosure of a transparency notification from Aberdeen Group plc Pursuant to the Belgian act of 2 May 2007 on the [...]
InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026
22/10/2026
Data from pre-clinical renal disease models demonstrate potential of izicopan for kidney protection Structural modeling provides new insight into izicopan’s differentiated molecular profile Jena, Germany, Oct. 22, 2026 [...]
Walden Biosciences Announces Positive Data from Diabetic Kidney Disease Cohorts in Ongoing Phase 2 Study of WAL0921
22/10/2026
Six of 12 evaluable participants receiving WAL0921 treatment experienced proteinuria (UACR) reduction greater than 20 percent; median 32.4 percent UACR reduction among responders Initial clinical results provide proof- [...]
SeaStar Medical Reports Statistically Significant Survival Findings from Post-Approval QUELIMMUNE® SAVE Registry Analysis in Pediatric Sepsis-Associated AKI
22/10/2026
New late-breaking data presented today at ASN Kidney Week 2026 QUELIMMUNE (SCD-PED) treatment group demonstrates statistically significant higher survival in the primary analysis at Day 60, Day 90, and at hospital [...]
BridgeBio to Report Third Quarter 2026 Financial Results and Commercial Updates on October 29, 2026 at 4:30 pm ET
22/10/2026
PALO ALTO, Calif., Oct. 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today [...]
Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026
22/10/2026
NORWOOD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that late breaking data [...]
Rgenta Therapeutics Announces Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Trial Design for RGT-61159 in Patients with Adenoid Cystic Carcinoma (ACC)
22/10/2026
Phase 3 trial alignment paves path toward New Drug Application and potential approval of RGT-61159, an oral small molecule targeting the MYB oncogene Prior preliminary data in patients treated at or below recommended [...]
Apyx Medical Corporation to Release Third Quarter of Fiscal Year 2026 Financial Results on November 5, 2026
22/10/2026
CLEARWATER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the “Company” or “Apyx Medical”), the leader in surgical aesthetics marketed and sold as Renuvion ® and the AYON Body [...]
Georgiamune and Menarini Group Enter Exclusive Global License and Collaboration Agreement for GIM-621, a First-in-Class Oral Immuno-Oncology Agent
22/10/2026
GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple solid tumors. Georgiamune to receive $45 million in upfront and near-term payments, as part of [...]
Annovis to Attend the CTAD 2026 with Three Presentations
22/10/2026
MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
Ignite Proteomics Enters Breast Cancer Research Collaboration with Leading Cancer Center
22/10/2026
Research Will Apply Ignite's RPPA-Based Proteomic Test to Study Treatment Response and Resistance GOLDEN, Colo., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ignite Proteomics, Inc. (“Ignite” or the “Company”), a precision [...]
Senseonics Holdings, Inc. to Participate in Upcoming Investor Conferences
22/10/2026
GERMANTOWN, Md., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose [...]
Celularity Regains Compliance with Nasdaq Periodic Reporting Requirement
22/10/2026
Nasdaq closes reporting deficiency following filing of second-quarter 2026 Form 10-Q FLORHAM PARK, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative [...]
LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
22/10/2026
SAN DIEGO, Oct. 22, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ ® (aceclidine ophthalmologic solution) 1. [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum